Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion

By Colin Kellaher

 

Johnson & Johnson has agreed to buy Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases, for an initial $2.2 billion, and has struck a deal with asset manager Blackstone to fund development of Ollin's lead asset.

J&J on Monday said the Ollin deal, which includes more than $1.12 billion in potential regulatory and commercial milestone payments, adds OLN324, an investigational bispecific antibody for retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema.

The New Brunswick, N.J., pharmaceutical giant said Blackstone's private investment platform Blackstone Life Sciences will pay $750 million over multiple years to fully fund the Phase 3 development of OLN324 in exchange for regulatory and sales milestone payments, along with single-digit royalties on sales.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

November 16, 2026 08:40 ET (13:40 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center